UNSPSC 51102806: Acetic acid/benzethonium/propylene glycol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT109. This VA Drug Class (OT109) classifies this compound as belonging to the group ANTI-INFECTIVES, TOPICAL OTIC OTHER.

UNSPSC 51102806 Acetic acid/benzethonium/propylene glycol is a Commodity code under which state and local governments procure pharmaceutical products, medical supplies, and over-the-counter formulations. Recent solicitations show purchasing activity centered on naloxone and drug deactivation systems for public health initiatives, generic multi-source pharmaceuticals distributed through cooperative purchasing agreements, and medical and first aid supplies for emergency response divisions. The issuing bodies span county health departments, state health commissions, municipal fire departments, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa Fire Department; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of agencies currently sourcing under this code, with MMCAP serving as a vehicle for coordinated multi-jurisdictional procurement across state and local participating entities.

Recent activity concentrates in Florida and the Upper Midwest, with Texas also active in preliminary market intelligence. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies totaling an estimated $700,000 with a 5 percent small local business enterprise discount; and the Minnesota Department of Administration's RFP S1070000015802 through MMCAP (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products distributed through authorized wholesalers with awards effective July 1, 2026. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs, signaling exploratory procurement before formal RFP issuance. Contracts typically run one to two years with renewal or extension options, include firm pricing with shipping included, and require compliance with cGMP, FDA requirements, and supply chain security standards.